BRPI0518209A - agentes de ligação especìficos à angiopoietina-2 - Google Patents

agentes de ligação especìficos à angiopoietina-2

Info

Publication number
BRPI0518209A
BRPI0518209A BRPI0518209-3A BRPI0518209A BRPI0518209A BR PI0518209 A BRPI0518209 A BR PI0518209A BR PI0518209 A BRPI0518209 A BR PI0518209A BR PI0518209 A BRPI0518209 A BR PI0518209A
Authority
BR
Brazil
Prior art keywords
specific binding
binding agents
angiopoietin
antibodies
disclosed
Prior art date
Application number
BRPI0518209-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Daniel Jonathon Oliner
Kevin Graham
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/982,440 external-priority patent/US7658924B2/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BRPI0518209A publication Critical patent/BRPI0518209A/pt

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0518209-3A 2004-10-19 2005-10-19 agentes de ligação especìficos à angiopoietina-2 BRPI0518209A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62016104P 2004-10-19 2004-10-19
US10/982,440 US7658924B2 (en) 2001-10-11 2004-11-04 Angiopoietin-2 specific binding agents
PCT/US2005/037911 WO2006045049A1 (en) 2004-10-19 2005-10-19 Angiopoietin-2 specific binding agents

Publications (1)

Publication Number Publication Date
BRPI0518209A true BRPI0518209A (pt) 2008-11-04

Family

ID=39608222

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518209-3A BRPI0518209A (pt) 2004-10-19 2005-10-19 agentes de ligação especìficos à angiopoietina-2

Country Status (10)

Country Link
JP (2) JP2008520188A (enExample)
CN (1) CN101495513B (enExample)
BR (1) BRPI0518209A (enExample)
EA (1) EA011866B1 (enExample)
IL (1) IL182279A0 (enExample)
MA (1) MA29015B1 (enExample)
MX (1) MX2007004247A (enExample)
RU (2) RU2404992C2 (enExample)
SG (1) SG156668A1 (enExample)
ZA (1) ZA200704020B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0518209A (pt) * 2004-10-19 2008-11-04 Amgen Inc agentes de ligação especìficos à angiopoietina-2
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
EA022546B1 (ru) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Способ торможения роста карциномы эрлиха у лабораторного животного
PE20142361A1 (es) * 2011-09-30 2015-01-16 Dana Farber Cancer Inst Inc Peptidos terapeuticos
AU2013212587B2 (en) * 2012-01-23 2017-07-20 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-Ang2 antibodies
US9534007B2 (en) 2012-12-21 2017-01-03 The Regents Of The University Of California Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
HRP20221047T1 (hr) 2014-08-28 2022-11-11 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
HUE064614T2 (hu) 2015-02-25 2024-04-28 Eisai R&D Man Co Ltd Eljárás egy kinolin-származék keserû ízének elnyomására
CA2978226C (en) 2015-03-04 2025-02-18 Eisai R&D Management Co., Ltd. COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR TO TREAT CANCER
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
MX381976B (es) 2015-08-20 2025-03-13 Eisai R&D Man Co Ltd Agente terapéutico contra tumores.
CN106512006A (zh) * 2016-07-25 2017-03-22 广州道瑞医药科技有限公司 Angpt2分泌抑制剂在制备用于治疗血管瘤的药物中的应用
CN106075448A (zh) * 2016-07-25 2016-11-09 广州道瑞医药科技有限公司 Angpt2抑制剂在制备用于治疗血管瘤的药物中的应用
KR102539920B1 (ko) 2017-02-08 2023-06-05 에자이 알앤드디 매니지먼트 가부시키가이샤 종양-치료용 약제학적 조성물
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
CN109096368B (zh) * 2018-09-30 2021-07-20 华南理工大学 一种同时具有抗氧化和护肝活性的多肽及编码该多肽的基因与其制备方法和应用
SG11202108832XA (en) * 2019-02-25 2021-09-29 Pharmabcine Inc Anti-ang2 antibody and use thereof
CN112126671B (zh) * 2020-08-18 2021-08-31 中山大学附属第五医院 无乳链球菌Streptococus agalactiae治疗子宫内膜异位症的应用
CN116265487B (zh) * 2021-12-16 2025-01-10 三优生物医药(上海)有限公司 抗ang2-vegf双特异性抗体及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2199804T3 (es) * 1999-03-26 2004-03-01 Regeneron Pharmaceuticals, Inc. Modulacion de la permeabilidad vascular por medio de activadores del receptor tie2.
CA2372053C (en) * 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
AU784231B2 (en) * 2000-06-23 2006-02-23 Schering Aktiengesellschaft Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use (II)
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
DK2332523T4 (da) * 2001-10-12 2022-02-21 Aquestive Therapeutics Inc Ensartede film til hurtigtopløsende doseringsform indeholdende smagsmaskerende præparater
BRPI0518209A (pt) * 2004-10-19 2008-11-04 Amgen Inc agentes de ligação especìficos à angiopoietina-2

Also Published As

Publication number Publication date
MA29015B1 (fr) 2007-11-01
EA200700876A1 (ru) 2007-10-26
IL182279A0 (en) 2007-07-24
SG156668A1 (en) 2009-11-26
JP2011207882A (ja) 2011-10-20
RU2404992C2 (ru) 2010-11-27
MX2007004247A (es) 2007-06-12
RU2007118670A (ru) 2008-12-27
RU2010132956A (ru) 2012-02-10
JP2008520188A (ja) 2008-06-19
EA011866B1 (ru) 2009-06-30
CN101495513A (zh) 2009-07-29
CN101495513B (zh) 2014-08-06
ZA200704020B (en) 2008-06-25

Similar Documents

Publication Publication Date Title
BRPI0518209A (pt) agentes de ligação especìficos à angiopoietina-2
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
CO6290772A2 (es) Anticuerpos dirigidos a angiopoietina 1 y angiopoietina 2 y usos de los mismos
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
EA201070888A1 (ru) Антитела и их производные
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
PT1766093E (pt) Anticorpos contra toxinas de clostridium difficile e utilizações dos mesmos
EA200970477A1 (ru) Человеческие моноклональные антитела к btla и способы применения
EA200801679A1 (ru) Композиции и способы применения антител к dickkopf-1 и/или -4
EA200702278A1 (ru) Антитела, специфичные в отношении tgf-бета 1
PH12014501927A1 (en) Antibodies to matrix metalloproteinase 9
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
CR20120105A (es) Proteínas terapéuticas de unión a dll4
EA201070695A1 (ru) Молекулы гуманизированных антител, специфичных к il-31
BR112015014751A2 (pt) anticorpos anti-tau humanos
BR112012009846B8 (pt) método in vitro e kit para detecção de um anticorpo antifármaco de isotipo ige, e uso de um anticorpo antifármaco de isotipo ige no tratamento de distúrbio mediado por ige
EA201491575A1 (ru) Антитела к матриксной металлопротеиназе 9
ATE504602T1 (de) Für humane matriptase spezifische bindungsproteine
MX2007013108A (es) Reactivos que enlazan ccx-ckr2.
CR20140081A (es) Agentes de fijación

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2153 DE 10/04/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.